NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Sees Significant Growth in Short Interest

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) saw a significant increase in short interest in the month of December. As of December 15th, there was short interest totaling 1,744,957 shares, an increase of 38.2% from the November 30th total of 1,262,366 shares. Currently, 7.3% of the company’s stock are short sold. Based on an average daily volume of 495,030 shares, the days-to-cover ratio is presently 3.5 days. Based on an average daily volume of 495,030 shares, the days-to-cover ratio is presently 3.5 days. Currently, 7.3% of the company’s stock are short sold.

Institutional Trading of NRx Pharmaceuticals

Large investors have recently bought and sold shares of the business. Anson Funds Management LP lifted its stake in shares of NRx Pharmaceuticals by 535.1% in the 1st quarter. Anson Funds Management LP now owns 1,179,061 shares of the company’s stock valued at $2,417,000 after purchasing an additional 993,401 shares during the period. Ethos Financial Group LLC acquired a new stake in NRx Pharmaceuticals during the third quarter worth approximately $39,000. One Wealth Management Investment & Advisory Services LLC increased its holdings in NRx Pharmaceuticals by 86.1% in the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock worth $92,000 after purchasing an additional 12,950 shares in the last quarter. AdvisorShares Investments LLC lifted its stake in NRx Pharmaceuticals by 29.7% in the third quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock valued at $1,129,000 after buying an additional 78,339 shares during the period. Finally, Two Sigma Investments LP boosted its holdings in shares of NRx Pharmaceuticals by 66.4% during the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after buying an additional 20,880 shares in the last quarter. 4.27% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently issued reports on NRXP shares. Zacks Research upgraded NRx Pharmaceuticals to a “hold” rating in a research report on Wednesday, September 10th. BTIG Research reiterated a “buy” rating and issued a $25.00 price target on shares of NRx Pharmaceuticals in a report on Wednesday, December 3rd. Ascendiant Capital Markets raised their price objective on shares of NRx Pharmaceuticals from $46.00 to $47.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research note on Monday. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of NRx Pharmaceuticals in a report on Tuesday, December 16th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $36.50.

NRx Pharmaceuticals Stock Performance

NASDAQ:NRXP traded up $0.03 during mid-day trading on Tuesday, reaching $2.63. 267,372 shares of the company’s stock were exchanged, compared to its average volume of 493,333. NRx Pharmaceuticals has a one year low of $1.47 and a one year high of $6.01. The business’s fifty day simple moving average is $2.50 and its two-hundred day simple moving average is $2.81. The firm has a market capitalization of $77.85 million, a PE ratio of -1.12 and a beta of 1.91.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its earnings results on Friday, November 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.07). The firm had revenue of $0.24 million during the quarter, compared to the consensus estimate of $6.83 million. As a group, equities research analysts forecast that NRx Pharmaceuticals will post -1.75 EPS for the current year.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.